Some blood tests first learn which DNA changes to track from a tumor sample. Others look for predefined signals without requiring that tumor-specific starting information.
Tumor-informed assays select features from a person's tumor; tumor-naive approaches use signals specified without that individual tumor profile. A primary breast cancer study compared several such assays on the same plasma samples and found method-dependent sensitivity at low concentrations. That comparison does not rank every commercial platform. Tissue availability, selected features, sampled molecules and intended clinical use all matter, while detection performance remains separate from evidence that acting on the result improves outcomes.
Showing the technology this term belongs to: Liquid biopsy (ctDNA).
Shares Finite-molecule sampling in blood tests, Evidence from measurement to patient benefit, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Finite-molecule sampling in blood tests, Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/